生物制药公司Axsome Therapeutics（AXSM）今日盘中股价大幅上涨5.03%，引起了市场参与者的关注。
消息面上，多家华尔街知名券商在今日发布的研究报告中，纷纷上调了该公司的目标股价。其中，Needham将目标价从225美元上调至255美元，H.C. Wainwright将目标价从260美元上调至270美元，德意志银行则将目标价从245美元大幅上调至281美元。分析师们集体上调目标价的行动，通常被视为对公司未来业绩和增长前景的积极预期，这直接提振了市场信心，推动了股价在交易时段内的强劲表现。
尽管相关研究报告未详细说明具体上调理由，但分析师集体看多的行为本身，向市场传递了积极的信号。投资者对此作出反应，导致该股在开盘后不久即出现显著上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.